Sesen Bio Up 23%
13 August 2021 - 5:22AM
Dow Jones News
By Josh Beckerman
Sesen Bio Inc. shares rose 23% to $4.97.
The company has said several times that it believes it is on
track for a U.S. Food and Drug Administration decision on Vicineum
by Aug. 18. A Biologics License Application for Vicineum for
treatment of BCG-unresponsive non-muscle invasive bladder cancer is
currently under Priority Review.
Sesen said early Wednesday that it was expanding its executive
leadership team in support of its "continued transformation into a
commercial-stage company."
Write to Josh Beckerman at josh.beckerman@wsj.com
(END) Dow Jones Newswires
August 12, 2021 15:16 ET (19:16 GMT)
Copyright (c) 2021 Dow Jones & Company, Inc.
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From Apr 2024 to May 2024
Sesen Bio (NASDAQ:SESN)
Historical Stock Chart
From May 2023 to May 2024